These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8888679)

  • 1. Low-dose heparin for routine coronary angioplasty and stenting.
    Vainer J; Fleisch M; Gunnes P; Ramamurthy S; Garachemani A; Kaufmann UP; Meyer BJ; Lüscher TF; Meier B
    Am J Cardiol; 1996 Oct; 78(8):964-6. PubMed ID: 8888679
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty.
    Boccara A; Benamer H; Juliard JM; Aubry P; Goy P; Himbert D; Karrillon GJ; Steg PG
    Eur Heart J; 1997 Apr; 18(4):631-5. PubMed ID: 9129894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.
    Ambrose JA; Doss R; Geagea JM; Hawkey MC; Duvuri S; Giedd K; Dominguez A; Coppola J; Nguyen TH; Palla V; Barua RS; Saha DC
    Am J Cardiol; 2001 May; 87(10):1231-3: A8. PubMed ID: 11356410
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Stent after-care: new approaches to coagulation inhibiting therapy].
    Mudra H
    Herz; 1995 Jun; 20(3):221-3. PubMed ID: 7635403
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimal heparinization in coronary angioplasty--how much heparin is really warranted?
    Kaluski E; Krakover R; Cotter G; Hendler A; Zyssman I; Milovanov O; Blatt A; Zimmerman E; Goldstein E; Nahman V; Vered Z
    Am J Cardiol; 2000 Apr; 85(8):953-6. PubMed ID: 10760333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two hour ambulation after coronary angioplasty and stenting with 6 F guiding catheters and low dose heparin.
    Koch KT; Piek JJ; de Winter RJ; Mulder K; Schotborgh CE; Tijssen JG; Lie KI
    Heart; 1999 Jan; 81(1):53-6. PubMed ID: 10220545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More on ACT.
    Aji J; Cha SD
    Cathet Cardiovasc Diagn; 1993 Nov; 30(3):268-9. PubMed ID: 8269504
    [No Abstract]   [Full Text] [Related]  

  • 9. Six hour ambulation after elective coronary angioplasty and stenting with 7F guiding catheters ald low dose heparin.
    Tengiz I; Ercan E; Bozdemir H; Durmaz O; Gurgun C; Nalbantgil I
    Kardiol Pol; 2003 Feb; 58(2):93-7. PubMed ID: 14504634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin dosing for percutaneous coronary angioplasty: use of body surface area to improve initial activated clotting time values.
    Pesola GR; Pesola DA
    Clin Cardiol; 1997 Dec; 20(12):1006-9. PubMed ID: 9422838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Unexpected complication of anticoagulation after implantation of a coronary stent].
    Utech A; Szczepaniec M; Bauer U; Sievert H
    Z Kardiol; 1992 Mar; 81(3):180-1. PubMed ID: 1585717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term patency of a Cook stent without anticoagulation.
    Ong LS; Om A
    J Invasive Cardiol; 1994 Oct; 6(8):257-9. PubMed ID: 10155078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel resistance: a new chapter in a fast-moving story.
    Wiviott SD; Antman EM
    Circulation; 2004 Jun; 109(25):3064-7. PubMed ID: 15226220
    [No Abstract]   [Full Text] [Related]  

  • 14. The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
    Davidson SJ; Turner N; Clague JR; Oldershaw PJ; Burman JF
    Thromb Haemost; 1999 Nov; 82(5):1560-1. PubMed ID: 10595660
    [No Abstract]   [Full Text] [Related]  

  • 15. Heparin delivery at the site of angioplasty with a novel drug delivery sleeve.
    Kaplan AV; Vandormael M; Hofmann M; Weil HJ; Störger H; Krajcar M; Gallant P; Simpson JB; Reifart N
    Am J Cardiol; 1996 Feb; 77(4):307-10. PubMed ID: 8607416
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
    Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
    Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of low dose heparin in elective coronary angioplasty.
    Koch KT; Piek JJ; de Winter RJ; David GK; Mulder K; Tijssen JG; Lie KI
    Heart; 1997 Jun; 77(6):517-22. PubMed ID: 9227294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive pharmacotherapy for coronary interventions-time to read the writing on the wall.
    Kaluski E; Hendler A; Uriel N; Milo-Cotter O; Vered Z; Krakover R; Cotter G
    Acute Card Care; 2006; 8(4):186-95. PubMed ID: 17162545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.